Literature DB >> 20554805

Mobilization of CD34+ progenitor cells in association with decreased proliferation in the bone marrow of macaques after administration of the Fms-like tyrosine kinase 3 ligand.

R Keith Reeves1, Qing Wei, Patricia N Fultz.   

Abstract

Fms-like tyrosine kinase 3 ligand (FLT3-L) is critical for the differentiation and self-renewal of CD34+ progenitor cells in primates and has been used therapeutically to mobilize progenitor and dendritic cells in vivo. However, little is known regarding the expansion of progenitor cells outside of peripheral blood, particularly in bone marrow (BM), where progenitor cells primarily reside. Evaluation of FLT3-L-mediated cell mobilization during lentivirus infections, where the numbers of CD34+ progenitor cells are reduced, is limited. We enumerated frequencies and absolute numbers of CD34+ progenitor cells in blood and BM of naive and SIV- or SHIV-infected macaques during and after the administration of FLT3-L. Flow cytometric analyses revealed that, while CD34+ cells increased in the circulation, no expansion was observed in BM. Furthermore, in the BM intracellular Ki67, a marker of cell proliferation, was downregulated in CD34+ progenitor cells but was upregulated significantly in the bulk cell population. Although the exact mechanism(s) remains unclear, these data suggest that CD34+ cell mobilization in blood was the result of cellular emigration from BM and not the proliferation of CD34+ cells already in the periphery. It is possible that the decreased progenitor cell proliferation observed in BM is evidence of a negative regulatory mechanism preventing hyperproliferation and development of neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554805      PMCID: PMC2916240          DOI: 10.1128/CVI.00166-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  44 in total

1.  In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor.

Authors:  T Papayannopoulou; B Nakamoto; R G Andrews; S D Lyman; M Y Lee
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  Engraftment and retroviral marking of CD34+ and CD34+CD38- human hematopoietic progenitors assessed in immune-deficient mice.

Authors:  M A Dao; A J Shah; G M Crooks; J A Nolta
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

3.  FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction.

Authors:  M A Dao; C H Hannum; D B Kohn; J A Nolta
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

4.  Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia.

Authors:  A Wodnar-Filipowicz; S D Lyman; A Gratwohl; A Tichelli; B Speck; C Nissen
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

5.  Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division.

Authors:  L J Murray; J C Young; L J Osborne; K M Luens; R Scollay; B L Hill
Journal:  Exp Hematol       Date:  1999-06       Impact factor: 3.084

6.  Cytokine manipulation of primitive human hematopoietic cell self-renewal.

Authors:  P W Zandstra; E Conneally; A L Petzer; J M Piret; C J Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.

Authors:  H Yu; T A Fehniger; P Fuchshuber; K S Thiel; E Vivier; W E Carson; M A Caligiuri
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  Hematologic and virologic effects of lineage-specific and non-lineage-specific recombinant human and rhesus cytokines in a cohort of SIVmac239-infected macaques.

Authors:  S Z Bucur; D A Lackey; J W Adams; M E Lee; F Villinger; A Mayne; R A Bray; E F Winton; F Novembre; E A Strobert; J De Rosayro; P J Dailey; A A Ansari; C D Hillyer
Journal:  AIDS Res Hum Retroviruses       Date:  1998-05-20       Impact factor: 2.205

9.  The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro.

Authors:  L S Rusten; S D Lyman; O P Veiby; S E Jacobsen
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

10.  Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor.

Authors:  R E Donahue; M R Kirby; M E Metzger; B A Agricola; S E Sellers; H M Cullis
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

View more
  1 in total

1.  Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.

Authors:  Amy Haseley Thorne; Kirsten N Malo; Ashley J Wong; Tricia T Nguyen; Neil Cooch; Charles Reed; Jian Yan; Kate E Broderick; Trevor R F Smith; Emma L Masteller; Laurent Humeau
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.